| thyroxine vs placebo | No demonstrated result suggested non cardiovascular death by 58% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Venous thromboembolism | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | stroke (fatal and non fatal) | no data | | Coronary event | no data | | Coronary death and non fatal MI | no data | | Coronary death | 1.09 [0.87 1.37] | p=1.00 | 0 | 3798 | 1 | CDP tyroxine, | | cardiac death | no data | | MACE | no data | | Non fatal MI | no data | | All cause death | 1.18 [0.97 1.45] | p=1.00 | 0 | 3798 | 1 | CDP tyroxine, | | non cardiovascular death | 1.58 [1.06 2.35] | p=0.04 | 0 | 3798 | 1 | CDP tyroxine, | | Fatal stroke | no data | | Haemmorhagic stroke | no data | | new-onset diabetes | no data | | Death from cancer | no data | | Rhabdomyolysis | no data | | Myopathy | no data | | Cancer | no data | | Adverse events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
